Is OPKO Health Inc. (NASDAQ:OPK) about to enter sunset?


Here is an analysis at the scorecard of OPKO Health Inc. (NASDAQ:OPK) for the recent quarter and analyst projections for the coming periods.

The firm generated sales of 296.1M%, implying a jump of 0.02%% compared to a analogous quarter a year ago. The revenue growth increased/declined by grow%.

To achieve the recorded sales of 296.1M% for the quarter, the firm incurred $172.73M in cost of goods. Hence, after considering the cost of sales, OPKO Health Inc. came with a gross income of $123.37M.

Let?s look into the technical of the stock

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction. Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

OPKO Health Inc. incurred other expenses in the completion of operation. Taking those into account, it closed the quarter with EPS of $(0.06). The firm had 558.43M diluted outstanding shares at the close of the quarter.

For the next quarter, analysts on the average are projecting EPS of $-0.05.

OPKO Health Inc.’s cash balance at the close of the recent quarter was 131.05M%. The firm generated free cash flow of $(43.46M) during the quarter, while net operating cash flow was $(33.92M). Net change in cash was $(37.68M).

That said, OPKO Health Inc. closed the quarter with debt of 14.86M%. The debt increased/dropped by growing from the past period.

What is market thinking about OPKO Health Inc.? So far 6 analysts have assessed the stock, and they have average recommendation of Buy and average price target of $15.42. To put the recommendation into perspective, call in the range of 1.00 – 1.24 indicates a BUY recommendation, whereas 1.25 – 1.74 refers to OVERWEIGHT. HOLD recommendation is shown by 1.75 – 2.24, UNDERWEIGHT is signified by 2.25 – 2.74 while SELL is signified by 2.75 – 3.00.

Does OPKO Health Inc. have a strong balance sheet? A look at the firm’s balance sheet at the close of the most recent quarter displays that it has total assets of $2.76B, offset by total liabilities of $653.1M.

OPKO’s plans for expansion to 70 field based nephrology sales representatives is proceeding by expanding in selective geographic areas as reimbursement coverage is secured. More extensive formulary coverage across Medicare Part D and commercial plans and the larger sales force will support continuing growth of RAYALDEE and provide greater access for adults with secondary hyperparathyroidism (SHPT), with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.